insights_auto
Why is 4547 down ३.३९%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥ ३,७००.००
arrow_downward
-३.३९%(-१३०.००) 1D
अक्टोबर २, १५:३०:०० GMT+९ · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥ ३,८१०
High
JP¥ ३,८१५
Low
JP¥ ३,६९०
Mkt. cap
१.७२ खरब
Avg. vol.
६६.५५ हजार
Volume
९७.५० हजार
Dividend
३.२४%
Quarterly dividend
JP¥ ३०
Ex-dividend date
२०२६ सेप्टेम्बर २९
P/E ratio
१०.९७
52-wk high
JP¥ ५,०४०
52-wk low
JP¥ ३,५००
EPS
JP¥ ३३७
Shares outstanding
४.६७ करोड
No. of employees
२ हजार
Open
JP¥ ३,८१०
High
JP¥ ३,८१५
Low
JP¥ ३,६९०
Mkt. cap
१.७२ खरब
Avg. vol.
६६.५५ हजार
Volume
९७.५० हजार
Dividend
३.२४%
Quarterly dividend
JP¥ ३०
Ex-dividend date
२०२६ सेप्टेम्बर २९
P/E ratio
१०.९७
52-wk high
JP¥ ५,०४०
52-wk low
JP¥ ३,५००
EPS
JP¥ ३३७
Shares outstanding
४.६७ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
marketscreener.com
·
१६ मिनेट पहिले
Vertical Aerospace Receives NYSE Noncompliance Notice
Business Wire
·
५ मिनेट पहिले
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Intellia Therapeutics
·
१ घण्टा पहिले
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor's Business Daily
·
१५ मिनेट पहिले
Nasdaq Pops After Jobs Report; Arrow, Materion, Advantest In Focus
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees१.७९ हजार
Founded१९४६ अगस्ट ९
HeadquartersMatsumoto, Nagano, जापान
Sector-
Websitekissei.co.jp